Wall Street brokerages predict that Healthequity Inc (NASDAQ:HQY) will report sales of $55.63 million for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Healthequity’s earnings, with the lowest sales estimate coming in at $54.79 million and the highest estimate coming in at $56.20 million. Healthequity reported sales of $43.36 million in the same quarter last year, which indicates a positive year over year growth rate of 28.3%. The company is scheduled to report its next quarterly earnings results on Tuesday, December 5th.

On average, analysts expect that Healthequity will report full-year sales of $55.63 million for the current fiscal year, with estimates ranging from $225.39 million to $227.95 million. For the next financial year, analysts expect that the business will report sales of $279.06 million per share, with estimates ranging from $271.53 million to $292.50 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Healthequity.

Healthequity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.13. The firm had revenue of $56.90 million for the quarter, compared to analysts’ expectations of $55.66 million. Healthequity had a net margin of 29.79% and a return on equity of 22.40%. The firm’s quarterly revenue was up 28.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.16 earnings per share.

Several equities research analysts have recently weighed in on HQY shares. BidaskClub raised Healthequity from a “sell” rating to a “hold” rating in a research report on Thursday, September 28th. Robert W. Baird reaffirmed a “hold” rating on shares of Healthequity in a research report on Thursday, September 21st. TheStreet raised shares of Healthequity from a “c” rating to a “b” rating in a research report on Monday, July 31st. Zacks Investment Research cut shares of Healthequity from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $56.00 price target on shares of Healthequity in a research report on Monday, September 25th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $56.50.

In other news, insider Stephen Neeleman sold 8,500 shares of the company’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $50.83, for a total transaction of $432,055.00. Following the transaction, the insider now owns 1,000 shares of the company’s stock, valued at $50,830. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Berkley Capital, Llc sold 210,398 shares of the firm’s stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $50.26, for a total value of $10,574,603.48. The disclosure for this sale can be found here. Insiders have sold a total of 1,550,851 shares of company stock valued at $78,530,968 in the last quarter. 19.00% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Fifth Third Bancorp lifted its position in Healthequity by 382.8% during the 1st quarter. Fifth Third Bancorp now owns 2,414 shares of the company’s stock valued at $102,000 after purchasing an additional 1,914 shares during the period. Oppenheimer Asset Management Inc. bought a new position in shares of Healthequity in the 1st quarter valued at about $106,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Healthequity by 105.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock worth $127,000 after buying an additional 1,308 shares during the period. Riverhead Capital Management LLC raised its stake in shares of Healthequity by 75.3% during the second quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock worth $131,000 after buying an additional 1,129 shares during the last quarter. Finally, Exane Derivatives bought a new stake in shares of Healthequity during the second quarter worth approximately $132,000. 90.97% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/04/healthequity-inc-hqy-expected-to-post-quarterly-sales-of-55-63-million.html.

Healthequity (NASDAQ HQY) traded up 0.37% during midday trading on Wednesday, hitting $52.13. 537,467 shares of the stock traded hands. The company has a 50-day moving average of $45.35 and a 200-day moving average of $46.40. Healthequity has a 1-year low of $30.34 and a 1-year high of $54.95. The stock has a market cap of $3.15 billion, a PE ratio of 77.34 and a beta of 1.80.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.